


# Cell Reports

## Deletions, Inversions, Duplications: Engineering of Structural Variants using CRISPR/Cas in Mice

### Graphical Abstract



### Authors

Katerina Kraft, Sinje Geuer, ...,  
Darío G. Lupiáñez, Guillaume Andrey

### Correspondence

[lupianez@molgen.mpg.de](mailto:lupianez@molgen.mpg.de) (D.G.L.),  
[andrey@molgen.mpg.de](mailto:andrey@molgen.mpg.de) (G.A.)

### In Brief

Kraft et al. now present a 10-week-long protocol to engineer deletions, inversions, and duplications over a megabase in mice. The authors generate ESCs carrying SVs and show that mice with deletion of *Laf4* recapitulate a human malformation.

### Highlights

- CRISVar allows the efficient generation of structural variations in ESCs
- ESCs carry duplications, inversions, deletions, or different combinations thereof
- ESC clones with specific SVs generate germline transmitting chimeras



# Deletions, Inversions, Duplications: Engineering of Structural Variants using CRISPR/Cas in Mice

Katerina Kraft,<sup>1,5</sup> Sinje Geuer,<sup>1,2,5</sup> Anja J. Will,<sup>1,2</sup> Wing Lee Chan,<sup>2</sup> Christina Paliou,<sup>1</sup> Marina Borschiwer,<sup>1</sup> Izabela Harabula,<sup>1</sup> Lars Wittler,<sup>1</sup> Martin Franke,<sup>1,2</sup> Daniel M. Ibrahim,<sup>1,3</sup> Bjørn K. Kragesteen,<sup>1,2,3</sup> Malte Spielmann,<sup>1,2,3,4</sup> Stefan Mundlos,<sup>1,2,3,4</sup> Darío G. Lupiáñez,<sup>1,6,\*</sup> and Guillaume Andrey<sup>1,6,\*</sup>

<sup>1</sup>Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany

<sup>2</sup>Institute for Medical and Human Genetics, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany

<sup>3</sup>Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany

<sup>4</sup>Berlin-Brandenburg School for Regenerative Therapies (BSRT), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany

<sup>5</sup>Co-first author

<sup>6</sup>Co-senior author

\*Correspondence: [lupianez@molgen.mpg.de](mailto:lupianez@molgen.mpg.de) (D.G.L.), [andrey@molgen.mpg.de](mailto:andrey@molgen.mpg.de) (G.A.)

<http://dx.doi.org/10.1016/j.celrep.2015.01.016>

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

## SUMMARY

Structural variations (SVs) contribute to the variability of our genome and are often associated with disease. Their study in model systems was hampered until now by labor-intensive genetic targeting procedures and multiple mouse crossing steps. Here we present the use of CRISPR/Cas for the fast (10 weeks) and efficient generation of SVs in mice. We specifically produced deletions, inversions, and also duplications at six different genomic loci ranging from 1.1 kb to 1.6 Mb with efficiencies up to 42%. After PCR-based selection, clones were successfully used to create mice via aggregation. To test the practicability of the method, we reproduced a human 500 kb disease-associated deletion and were able to recapitulate the human phenotype in mice. Furthermore, we evaluated the regulatory potential of a large genomic interval by deleting a 1.5 Mb fragment. The method presented permits rapid in vivo modeling of genomic rearrangements.


## INTRODUCTION

Genomic structural variations (SVs) are large-scale structural differences in the genomic DNA ranging in size from a few kilobases to entire chromosomes. SVs may be unbalanced as in deletions, duplications, and insertions or balanced as in inversions and translocations or a combination thereof. SVs contribute to a large extent to the variability of our genome and are often associated with disease (Stankiewicz and Lupski, 2010). When occurring within the coding sequence of genes, they can affect the protein sequence and thereby protein function or stability. When encompassing one or several coding units, deletions or duplications lead to changes in gene dosage. Furthermore, it was shown that SVs could interfere with gene regulation by disrupting genomic architecture neces-

sary for proper enhancer-promoter interactions. Such rearrangements can result in loss of WT interactions and/or ectopic enhancer-promoter interactions, thereby resulting in gene misexpression (Montavon et al., 2012; Spielmann et al., 2012; Spielmann and Mundlos, 2013). To discriminate between these multiple effects and to study their complex molecular pathology in vivo modeling of SVs is required.

SVs can be induced by radiation via the induction of double-strand breaks, but this is a random process that cannot be targeted to specific genomic regions. So far, allelic series involving the remodeling of large DNA segments have been obtained from the *cis* and *trans* recombination of targeted *loxP* sites in mouse chromosomes (Hérault et al., 1998; Ruf et al., 2011; Spitz et al., 2005). However, these approaches are time consuming and laborious, involving the targeting of *loxP* sequences and subsequent mice crossings with *Cre* driver animals, a procedure taking at least 12 months. More recently, Zinc Finger nucleases (ZNF) or transcription activator-like effector nucleases (TALENs) have been shown to induce targeted SVs of several hundred kilobases in mammalian cells. In vivo inversions and deletions up to 1 Mb could be obtained in zebrafish (Bauer et al., 2013; Gupta et al., 2013; Lee et al., 2012; Xiao et al., 2013). However, to our knowledge, these methods were not applied to generate large structural variants in mice. This might be due to the process of generating specific ZNF nucleases or TALEN that is rather slow and requires expert knowledge.

The recent development of the CRISPR/Cas technology has led to a wider use of genome editing, opening new possibilities to engineer SVs in various model systems (Hsu et al., 2014; Peng et al., 2014; Wang et al., 2013). Indeed, two synthetic guide RNAs (sgRNAs), targeted at two different positions of a chromosome, are able to induce inversions and deletions through non-homologous end joining (NHEJ). For instance, Xiao et al. (2013) were able to induce 1.5 kb deletions in zebrafish embryos by injecting sgRNAs and Cas9 directly into zygotes. Similarly, larger structural rearrangements involving deletions, inversions, and translocations were obtained in HEK293 or in murine eurythro-leukemia (MEL) cell lines (Canver et al., 2014; Choi and Meyer-son, 2014).



**Figure 1. Two sgRNAs Can Induce Structural Variants of the Intermediate Genomic Region**

(A) Overview and timing of CRISVar to obtain SVs in mouse.

(B) A 232 kb region at the *Pitx1* locus targeted for deletion, inversion, and duplication. Cas9 proteins and sgRNAs are depicted in yellow.

(C) PCR amplifications of breakpoints from the different genetic configurations (DEL, deletion; DUP, duplication; INV A, inversion breakpoint A; INV B, inversion breakpoint B). BRP (breakpoints) A and B represent the WT product at the CRISPR target sites.

(D) Genetic variability at the rearranged and WT breakpoints. SgRNAs are marked in green or red. Sequences of three clones are shown for each type of junction. See also [Figure S1](#) and [Table S1](#).

In this study, we applied the CRISPR/Cas technology in mouse embryonic stem cells (ESCs) and developed a 10-week protocol that we named CRISVar (CRISPR/Cas-induced structural variants) to efficiently produce deletions, inversions, and duplications in mice. We were able to rearrange targeted genomic intervals ranging from 1 kb to 1.6 Mb using the CRISPR/Cas system in ESCs ([Figure 1A](#)). Moreover, we show that ESCs harboring these mutations can be used to create chimeric animals. Finally, we show at the *Laf4* and *Epha4* loci the ability of CRISVar to model human pathogenic SVs and to evaluate the regulatory influence of a large gene desert, respectively.

## RESULTS

### CRISPR/Cas for the Induction of SVs in Mouse ESCs

To test the ability of CRISPR/Cas to generate structural variants in mice, we first targeted the pleiotropic and developmentally associated locus *Pitx1*. We designed two sgRNAs in the gene desert adjacent and telomeric to *Pitx1* promoter. The two-targeted sites are separated by 232 kb of intermediate gene desert. After transfection of ESCs with the CRISPR constructs, we screened 288 clones for inversions, deletions, and duplications using a PCR-based approach ([Figures 1B](#) and [S1](#)). We detected

**Table 1. Synthesis of Targeted SVs Efficiencies**

Name of the Locus	<i>H2afy</i>	<i>Bmp2</i>	<i>lhh</i>	<i>Pitx1</i>	<i>Laf4</i>	<i>Epha4</i>
CRISPR vector	pX330	pX330	pX459	pX459	pX459	pX330
Size of the rearranged region	1,189 bp	3.7 kb	12.6 kb	32 kb	353kb	1.672 Mb
Deleted	11 (3.8%)	12 (6.3%)	121 (42%)	9 (3.1%)	38 (13.2%)	4 (2.1%)
Inverted (two breakpoints mapped)	2 (0.7%)	3 (1.6%)	7 (2.4%)	3 (1%)	12 (4.2%)	3 (1.6%)
Inverted (one breakpoint mapped)	0 (0%)	0 (0%)	9 (3.1%)	8 (2.8%)	20 (6.9%)	1 (0.5%)
Duplicated	0 (0%)	0 (0%)	0 (0%)	2 (0.7%)	81 (28.1%)	0 (0%)
Deleted/inverted (two breakpoints mapped)	1 (0.3%)	1 (0.5%)	3 (1.0%)	0 (0%)	11 (3.8%)	0 (0%)
Deleted/inverted (one breakpoint mapped)	0 (0%)	1 (0.5%)	2 (0.7%)	1 (0.3%)	9 (3.1%)	0 (0%)
Deleted/duplicated	1 (0.3%)	0 (0%)	1 (0.3%)	4 (1.4%)	28 (10%)	0 (0%)
Inverted/duplicated (two breakpoints mapped)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	6 (2.1%)	0 (0%)
Inverted/duplicated (one breakpoint mapped)	0 (0%)	0 (0%)	0 (0%)	2 (0.7%)	17 (5.9%)	0 (0%)
Number of screened clones	288	192	288	288	288	192
Successfully aggregated clones	one deletion -	- -	- -	one inversion one deletion	two deletions one duplication	one inversion one deletion

Numbers and percentages are indicated for each type of rearrangements at every locus. Deletions and inversions were found in all cases. Duplications were identified in four of six loci. The number of successfully aggregated clones for each allele is indicated in the bottom track.

and sequenced junctions from all three types of structural variants (Figures 1C and 1D). Deletions and inversions were found most frequently (5%) followed by duplications (3%). Unexpectedly, not all inversion breakpoints could be mapped (Table 1).

SVs did not always segregate with a WT allele but were often found accompanied by other SVs on the homologous chromosome. For instance, one of the clones harbored a deletion and an inversion, indicating that NHEJ occurred simultaneously in the two homologous chromosomes. The absence of the WT variant in this clone was confirmed by the loss of PCR product at both sgRNA binding sites (Figure 1C). Another interesting phenomenon was observed in some of the duplicated alleles. Duplications originate from translocations between homologous chromosomes; thereby one of the chromosomes loses a copy of the rearranged DNA while the other gains it. In our experiments, duplications segregated with a deletion in only half of the cases. In the others, we found duplications segregating with an inverted or a WT homologous region (Figure 1C). A similar observation was described using ZNF nucleases in mammalian cells (Lee et al., 2012).

Sequencing of the junction products revealed diversity of the genomic position where the NHEJ had occurred as well as loss of DNA segments (Figure 1D). Double-strand breaks induced by the Cas9 endonuclease at their target sites were shown to result in local indels, thereby explaining the allele-to-allele variability (Canver et al., 2014). Moreover, sequence changes were also observed in alleles genotyped as WT, suggesting defective repair (Figure 1D).


After successfully implementing CRISVar at the *Pitx1* locus, we targeted other regions of the genome to rule out the possibility that the observed effects were locus specific. We aimed at regions near the genes *H2afy*, *Bmp2*, *lhh*, *Laf4* and *Epha4* (Figure 2)

with rearrangements of 1.1 kb, 3.7 kb, 12.6 kb, 353 kb, and 1.6 Mb, respectively (Table 1). Interestingly, the frequency at which SVs occurred was different from one locus to another without evident relation to the genomic distance separating the two CRISPR sites. We observed deletions and inversions at all sites, although with a variation in their frequency of around 10-fold between experiments. Duplications were observed at three of these five rearranged loci.

Next, we wanted to test whether the here-produced clones could be used to create viable animals. We aggregated ESCs from eight selected clones to produce animals carrying deletions, duplication, and inversions at the above-mentioned loci. We were able to produce highly chimeric animals for all rearrangement types and loci (Table 1). In our hands, all aggregated ESC clones performed to produce chimeric animals.

### A 353 kb Intragenic Deletion of *Laf4* Recapitulates a Human Malformation Syndrome

In order to confirm the effectiveness of this genetic tool to generate mouse models, we aimed at reproducing a human disease-associated SV of unknown pathogenicity (Steichen-Gersdorf et al., 2008). The SV had occurred de novo, but its functional relevance remained unclear. The patient suffered from multiple malformations, including shortening of the femur, aplasia of the fibula, a triangular tibia, and three toes (Figure 3B). Because of the tibia malformation, the diagnosis of a Nievergelt-like syndrome was made. To evaluate the function of LAF4, we first produced a conventional knockout by targeted recombination. We could not observe a phenotype in homozygous mice, showing that inactivation of *Laf4* cannot reproduce the human phenotype in the mouse (data not shown). We therefore re-evaluated the published data and found that the deletion was smaller than



**Figure 2. Rearrangements at Other Loci**

Summary of the other alleles in which SVs were induced. The alleles are ordered from the smallest generated SV (top: *H2afy*) to the largest (bottom: *Epha4*). Sizes of the rearranged regions are indicated next to the locus name.

originally thought, encompassing only nine exons of the *LAF4* gene and not the entire genomic region. The breakpoints of this 500 kb deletion were mapped in introns 3 and 12, thus eliminating exons 4 to 12 of *LAF4* without introducing a frameshift. The predicted product is a truncated 850 amino acids protein lacking a domain predicted to be involved in transcription activation (Ma and Staudt, 1996). To specifically model this SV, we designed sgRNA at the homologous regions in the mouse genome corresponding to the human breakpoints (Figures 2 and 3A). The screening of ESCs revealed clones with heterozygous and homozygous deletions of the 353 kb homologous region. In chimeric animals generated from heterozygous as well as homozygous clones, we observed a short zeugopod in the upper limb (Figure 3C). The lower-limb abnormalities recapitulated part of the human phenotype showing a small, triangular ossification center of the tibia and severe hypoplasia of the fibula (Figure 3C). In contrast to the patient, the mice had polydactyly of the feet with incomplete penetrance. Thus, the specific intragenic deletion in *Laf4* generated by CRISPR/Cas recapitulated the patient's phenotype, demonstrating the pathogenicity of this SV. It is likely that the truncated protein exerts a dominant-negative effect, thereby leading to the observed abnormalities of bone formation.

### A 1.5 Mb Deletion of a Gene Desert Encompassing *Epha4* Results in Hindlimb Hopping Gait

Large gene deserts are thought to harbor regulatory elements and often surround developmentally active genes. We aimed at using the here-described method to challenge the integrity of such a locus. At the *Epha4/Pax3* extended locus, two gene deserts centromeric and telomeric to *Epha4* might regulate either one or both genes. *Epha4* has been shown to control neuronal guidance in hindlimbs. *Pax3* is a transcription factor with important function in the migration of muscle progenitors in the limbs and neural crest migration. Mice with mutations in *Pax3* show pigmentation defects, early lethality due to heart defects, spina bifida, and exencephaly. We induced a deletion extending 1 Mb centromeric and 350 kb telomeric to the *Epha4*


transcription unit (Figure 4A). Heterozygous clones were used to produce mice with a 1.5 Mb deletion, which were subsequently bred to homozygosity. We observed a neurological phenotype in these animals, consisting of a hopping gait, as previously described for *Epha4* loss of function (Figure 4B; Movie S1) (Dottori et al., 1998). Other abnormalities were not observed in these mice. In particular, we did not detect any of the *Pax3*-associated phenotypes such as pigmentation defects and abnormalities of the spine or the brain. Furthermore, in situ hybridization of *Pax3* in deletion embryos revealed a normal pattern of expression (data not shown). Our finding that the 1.5 Mb deletion results in a full recapitulation of the *Epha4* knockout without additional abnormalities indicates that the region does not contain elements essential for *Pax3* regulation.

## DISCUSSION

CRISPR/Cas is a rapid and efficient method to specifically edit genomes (Cho et al., 2013; Wang et al., 2013). Here we show that by targeting two sgRNAs at two distal genomic sites we can induce the rearrangement of the intermediate DNA fragment up to 1.6 Mb in ESCs. We show that duplications, deletions, and inversions can be obtained in different clones, but they may also occur in various combinations together.

We observed extensive variability in the targeting efficiency from one locus to another. Although the size of the re-arranged DNA region was previously shown to play an important role in targeting efficiency, we were not able to confirm this relationship (Canver et al., 2014). One of the possibilities is that the chromatin "openness" at the CRISPR target site affects the cutting efficiency of Cas9 and thereby increases the probability of NHEJ between the two distal breakpoints. In fact, it has been shown that Cas9 binds better at open chromatin sites, where it has higher off-target effects (Kuscu et al., 2014). In this view, the epigenetic status of the targeted region might influence the overall efficiency of the rearrangement.

Furthermore, we frequently found sequence variations at the SV breakpoints. The randomness of NHEJ after a double-strand break is likely to be accountable for this diversity. This might also explain why several inverted clones could be mapped at a single breakpoint only: the other one being too extensively modified for a proper PCR reaction to occur. This variability in the NHEJ process also pinpoints to the limitations of PCR-oriented allele detection; indeed, several false-negative clones with deletions, duplications, or inversions may have been missed because of



**Figure 3. A 350 kb Deletion at the *Laf4* Locus Recapitulates Nievergelt Syndrome**

(A) Schematic of the extended *Laf4* genomic region. CRISPR/Cas binding sites are depicted in yellow. The induced deletion (350 kb) is shown below.

(B) Radiograph of patient lower leg showing triangular tibia, missing fibula, and oligodactyly.

(C) Skeletal preparations of WT and mutant embryos at E16.5. Cartilage is shown in blue and bone in red. Note the short ulna and radius with small ossification centers in forelimb and triangular tibia (magnification shown on right) and severely hypoplastic fibula in hindlimb.

See also Table S2.

extensive rearrangements at their breakpoints, inhibiting proper PCR reactions to occur. Because of this uncertainty, these clones were not processed further and discarded. Given the high efficiency of CRISVar, this was not considered a problem. We also observed that WT alleles might harbor indels induced by CRISPR/Cas. Thus, the WT allele should also be sequenced at the target site.

The limitations of CRISVar can be efficiently bypassed by a proper screening of ESC clones and subsequent mouse crossing. Such extensive screening might be a limiting step if the method would be applied directly to mouse zygotes. However, it is unclear how efficient microinjections of sgRNAs and Cas9 directly into embryos would be. Further testing is thus required to compare the efficiency of both approaches. The advantages of producing SVs in ESCs are on the one hand the possibility of retargeting to introduce additional mutations and on the other hand the direct use of these cells in culture to investigate the effects of SVs.

Thus, with CRISVar, large and small SVs of various types can be produced with high efficiency and in a short time period to study the effect of genomic rearrangements and their pathogenic effect. As shown at the *Laf4* locus, human SVs may exert their effects in a specific manner, necessitating an exact reproduction in the mouse genome to evaluate their pathogenicity. CRISPR/Cas-mediated genome editing can be used to efficiently create such rearrangements. Finally, as shown in the *Epha4* example, the method can be used to challenge the integrity of genomic regulatory units, as they have recently been proposed (Marinić et al., 2013).

## EXPERIMENTAL PROCEDURES

### CRISPR sgRNAs Selection and Cloning

SgRNAs were designed flanking the regions to rearrange. We used the <http://crispr.mit.edu/> platform to obtain candidate sgRNA sequences with little off-target specificity. Complementary strands were annealed, phosphorylated, and cloned into the BbsI site of pX459 or pX330 CRISPR/Cas vector (Addgene; see Table 1).


### ES Cell Culture and Transfection

G4 ESCs (300,000) (George et al., 2007) were seeded on CD1 feeders and transfected with 8  $\mu$ g of each CRISPR construct using FuGENE technology (Promega). When the construct originated from the pX330 vector, cells were cotransfected with a puromycin-resistant plasmid, PX459, in contrast, already contains a puromycin-resistance cassette. After 24 hr, cells were split and transferred onto DR4 puro-resistant feeders and selected with puromycin for 2 days. Clones were then grown for 5 to 6 more days, picked, and transferred into 96-well plates on CD-1 feeders. After 2 days of culture, plates were split in triplicates, two for freezing and one for growth and DNA harvesting.

Positive clones were thawed and grown on CD-1 feeders until they reach an average of four million cells. Three vials were frozen, and DNA was harvested from the rest of the cells to confirm genotyping.

### PCR-Based Genotyping

Primers were designed on both sides of sgRNAs targets, at a distance of 100–300 bp from the cutting site. Each allele has thus a set of four primers: T1 (fwd)/T2 (rev) amplifying one targeted site and T3 (fwd)/T4 (rev) amplifying the other (Figure S1; Table S1). Deletions were mapped using T1 and T4 primers while inversions were detected with T2/T4 for the proximal breakpoints and T1/T3 for the distal one. Finally, duplications were detected with T2/T3 primers. Positive PCR bands were Sanger sequenced using one of the amplification primers.



**Figure 4. CRISPR/Cas-Induced 1.5 Mb Deletion at the *Epha4* Locus**

(A) Schematic of the extended *Epha4/Pax3* genomic region. CRISPR/Cas binding sites are depicted in yellow. The induced deletion (1.5 Mb) is shown below.

(B) The deletion of a 1.5 Mb region containing the *Epha4* gene and surrounding gene desert results in a phenocopy of *Epha4* knockout mouse but no other abnormalities. Footprints of hindlimbs show hopping gait in deletion mutant.

See also [Movie S1](#).

#### Screening for *Laf4* Homozygote Deletion Clones

Quantification of copy-number variation of the deleted interval in comparison to other genomic positions was performed with a set of qPCR primers (see [Table S2](#)).

#### Mouse Aggregation

A frozen ESC vial was seeded on CD-1 feeders, and cells were grown for 2 days. Mice were generated by diploid or tetraploid aggregation ([Artus and Hadjantonakis, 2011](#)). All animal procedures were in accordance with institutional, state, and government regulations (LAGeSo).

#### Leg Footprints

Adult mice were encouraged to run over a white paper sheet after their hindfeet were soaked in blue ink.

#### Skeletal Preparation

E16.5 animals were processed and stained as described previously ([Mundlos, 2000](#)).

#### SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, one figure, two tables, and one movie and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2015.01.016>.

#### AUTHOR CONTRIBUTIONS

K.K. designed, produced, and analyzed the *Epha4* 1.5 Mb deletion. S.G. designed, produced, and analyzed the *Laf4* truncation. W.L.C. performed the *Laf4* knockout. K.K., A.J.W., S.G., M.F., D.M.I., M.S., S.M., D.G.L., and G.A. designed the research. L.W. performed aggregations. K.K., A.J.W., S.G., C.P., M.B., I.H., M.F., D.M.I., B.K.K., D.G.L., and G.A. performed the other experiments. K.K., S.M., D.G.L., and G.A. wrote the manuscript.

#### ACKNOWLEDGMENTS

We thank Phillip Grote and Tracie Pennimpede for discussions, advice, and sharing reagents. We thank Asita Stiege for technical assistance. G.A. is supported by an Early Postdoc.Mobility grant from the Swiss National Science Foundation. D.G.L. is supported by the Fundación Alfonso Martín Escudero. This research was supported by a grant from the Deutsche Forschungsgemeinschaft to S.M.

Received: November 17, 2014

Revised: January 5, 2015

Accepted: January 7, 2015

Published: February 5, 2015

#### REFERENCES

- Artus, J., and Hadjantonakis, A.K. (2011). Generation of chimeras by aggregation of embryonic stem cells with diploid or tetraploid mouse embryos. *Methods Mol. Biol.* 693, 37–56.
- Bauer, D.E., Kamran, S.C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M.C., Smith, E.C., Pinello, L., et al. (2013). An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. *Science* 342, 253–257.
- Canver, M.C., Bauer, D.E., Dass, A., Yien, Y.Y., Chung, J., Masuda, T., Maeda, T., Paw, B.H., and Orkin, S.H. (2014). Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. *J. Biol. Chem.* 289, 21312–21324.
- Cho, S.W., Kim, S., Kim, J.M., and Kim, J.S. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nat. Biotechnol.* 31, 230–232.
- Choi, P.S., and Meyerson, M. (2014). Targeted genomic rearrangements using CRISPR/Cas technology. *Nat. Commun.* 5, 3728.
- Dottori, M., Hartley, L., Galea, M., Paxinos, G., Polizzotto, M., Kilpatrick, T., Bartlett, P.F., Murphy, M., Köntgen, F., and Boyd, A.W. (1998). EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract. *Proc. Natl. Acad. Sci. USA* 95, 13248–13253.
- George, S.H., Gertsenstein, M., Vintersten, K., Korets-Smith, E., Murphy, J., Stevens, M.E., Haigh, J.J., and Nagy, A. (2007). Developmental and adult phenotyping directly from mutant embryonic stem cells. *Proc. Natl. Acad. Sci. USA* 104, 4455–4460.
- Gupta, A., Hall, V.L., Kok, F.O., Shin, M., McNulty, J.C., Lawson, N.D., and Wolfe, S.A. (2013). Targeted chromosomal deletions and inversions in zebrafish. *Genome Res.* 23, 1008–1017.
- Hérault, Y., Rassoulzadegan, M., Cuzin, F., and Duboule, D. (1998). Engineering chromosomes in mice through targeted meiotic recombination (TAMERE). *Nat. Genet.* 20, 381–384.
- Hsu, P.D., Lander, E.S., and Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. *Cell* 157, 1262–1278.

- Kuscu, C., Arslan, S., Singh, R., Thorpe, J., and Adli, M. (2014). Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. *Nat. Biotechnol.* *32*, 677–683.
- Lee, H.J., Kweon, J., Kim, E., Kim, S., and Kim, J.S. (2012). Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases. *Genome Res.* *22*, 539–548.
- Ma, C., and Staudt, L.M. (1996). LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias. *Blood* *87*, 734–745.
- Marinić, M., Aktas, T., Ruf, S., and Spitz, F. (2013). An integrated holoenhancer unit defines tissue and gene specificity of the Fgf8 regulatory landscape. *Dev. Cell* *24*, 530–542.
- Montavon, T., Thevenet, L., and Duboule, D. (2012). Impact of copy number variations (CNVs) on long-range gene regulation at the HoxD locus. *Proc. Natl. Acad. Sci. USA* *109*, 20204–20211.
- Mundlos, S. (2000). Skeletal morphogenesis. *Methods Mol. Biol.* *136*, 61–70.
- Peng, Y., Clark, K.J., Campbell, J.M., Panetta, M.R., Guo, Y., and Ekker, S.C. (2014). Making designer mutants in model organisms. *Development* *141*, 4042–4054.
- Ruf, S., Symmons, O., Uslu, V.V., Dolle, D., Hot, C., Ettwiller, L., and Spitz, F. (2011). Large-scale analysis of the regulatory architecture of the mouse genome with a transposon-associated sensor. *Nat. Genet.* *43*, 379–386.
- Spielmann, M., and Mundlos, S. (2013). Structural variations, the regulatory landscape of the genome and their alteration in human disease. *BioEssays* *35*, 533–543.
- Spielmann, M., Brancati, F., Krawitz, P.M., Robinson, P.N., Ibrahim, D.M., Franke, M., Hecht, J., Lohan, S., Dathe, K., Nardone, A.M., et al. (2012). Homeotic arm-to-leg transformation associated with genomic rearrangements at the PITX1 locus. *Am. J. Hum. Genet.* *91*, 629–635.
- Spitz, F., Herkenne, C., Morris, M.A., and Duboule, D. (2005). Inversion-induced disruption of the Hoxd cluster leads to the partition of regulatory landscapes. *Nat. Genet.* *37*, 889–893.
- Stankiewicz, P., and Lupski, J.R. (2010). Structural variation in the human genome and its role in disease. *Annu. Rev. Med.* *61*, 437–455.
- Steichen-Gersdorf, E., Gassner, I., Superti-Furga, A., Ullmann, R., Stricker, S., Klopocki, E., and Mundlos, S. (2008). Triangular tibia with fibular aplasia associated with a microdeletion on 2q11.2 encompassing LAF4. *Clin. Genet.* *74*, 560–565.
- Wang, H., Yang, H., Shivalila, C.S., Dawlaty, M.M., Cheng, A.W., Zhang, F., and Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* *153*, 910–918.
- Xiao, A., Wang, Z., Hu, Y., Wu, Y., Luo, Z., Yang, Z., Zu, Y., Li, W., Huang, P., Tong, X., et al. (2013). Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. *Nucleic Acids Res.* *41*, e141.